Evidence map›Paper›PMID 35425705›Full record

ArticleFrontiers in oncology2022

PCW-1001, a Novel Pyrazole Derivative, Exerts Antitumor and Radio-Sensitizing Activities in Breast Cancer.

Minsung Kang, Navin Pandit, Ah-Young Kim, Suk Joon Cho, Young-Ju Kwon, Jiyeon Ahn, Kyu Myung Lee, Sangwook Wu, Jeong Su Oh, Kwan-Young Jung and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. PCW-A1001, AI-assistedFrontiers in molecular biosciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Minsung KangDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.
Navin PanditDepartment of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon, South Korea.
Ah-Young KimDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.
Suk Joon ChoTherapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, South Korea.
Young-Ju KwonDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.
Jiyeon AhnDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.
Kyu Myung LeeTherapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, South Korea.
Sangwook WuResearch & Development (R&D) Center, Pharmcadd, Busan, South Korea.
Jeong Su OhDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, South Korea.
Kwan-Young JungDepartment of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon, South Korea.
Jae-Sung KimDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As pyrazole and its derivatives have a wide range of biological activities, including anticancer activity, the design of novel pyrazole derivatives has emerged as an important research field. This study describes a novel pyrazole derivative that exerts antitumor and radiosensitizing activities in breast cancer both

Indexed as

breast cancerchemotherapycombination therapypyrazole derivativeradio-sensitizer

Identifiers

PMID35425705
PMCPMC9002139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.